Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 5/20 | 0.48 |
| ▸ | CYP3A5 | P20815 | 3/20 | 0.48 |
| ▸ | KCNA5 | P22460 | 6/20 | 0.46 |
| ▸ | CYP19A1 | P11511 | 5/20 | 0.46 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.41 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.41 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.41 |
| ▸ | KCNH2 | Q12809 | 3/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.40 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9770755 | 0.81 | CYP3A4 (0.43) | CYP3A4CYP3A5KCNA5CYP19A1POLB | |
| SCHEMBL30431325 | 0.78 | CYP19A1 (0.47) | CYP3A4CYP3A5KCNA5CYP19A1POLB | |
| SCHEMBL21457779 | 0.78 | CYP19A1 (0.47) | CYP3A4CYP3A5KCNA5CYP19A1POLB | |
| SCHEMBL27609994 | 0.75 | CYP19A1 (0.55) | CYP3A4CYP3A5KCNA5CYP19A1CYP1A2 | |
| SCHEMBL19627972 | 0.73 | CYP19A1 (0.57) | CYP3A4CYP3A5KCNA5CYP19A1CYP1A2 | |
| SCHEMBL24608491 | 0.73 | CYP19A1 (0.50) | CYP3A4CYP3A5CYP19A1CYP1A2LMNA | |
| SCHEMBL30589181 | 0.73 | CYP19A1 (0.50) | CYP3A4CYP3A5CYP19A1CYP1A2LMNA | |
| SCHEMBL11147179 | 0.73 | KCNA5 (0.47) | CYP3A4CYP3A5KCNA5CYP19A1CYP1A2 | |
| SCHEMBL27404978 | 0.73 | KCNA5 (0.47) | CYP3A4CYP3A5KCNA5CYP19A1CYP1A2 | |
| SCHEMBL30911310 | 0.73 | KCNA5 (0.47) | CYP3A4CYP3A5KCNA5CYP19A1CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0734259-B1 | Use of piperidine compounds in the treatment of schizophrenia | NOVO NORDISK AS (DK) | 2002-06-12 | — | — | EP | disclosed |
| US-RE36375-E | Treatment of Alzheimer's disease using azacyclic compounds | NOVO NORDISK A/S (DK) | 1999-11-02 | — | — | US | disclosed |
| US-5919805-A | 3-OXY- OR THIO-DERIVATIVES OF 1,2,5-OXADIAZOLES OR 1,2,5-THIADIAZOLES; TREATMENT OF ALZHEIMER'S DISEASE, SEVERE PAINFUL CONDITIONS AND GLAUCOMA. | NOVO NORDISK A/S (DK) | 1999-07-06 | — | — | US | disclosed |
| US-5773452-A | ALZHEIMER'S DISEASE; COGNITION ACTIVATORS | NOVO NORDISK ALS (DK) | 1998-06-30 | — | — | US | disclosed |
| US-RE35822-E | COGNITION ACTIVATORS | NOVO NORDISK A/S (DK) | 1998-06-09 | — | — | US | disclosed |
| US-5753683-A | SCHIZOPHRENIA | NOVO NORDISK A/S (DK) | 1998-05-19 | — | — | US | disclosed |
| US-5750541-A | 3-(1,2,5-THIA OR OXADIAZOL-3-YL)-1,2,5,6-PYRIDINE DERIVATIVES; SCHIZOPHRENIFORM DISEASES; SIDE EFFECT REDUCTION | NOVO NORDISK A/S (DK) | 1998-05-12 | — | — | US | disclosed |
| US-5744489-A | ADMINISTERING CERTAIN 1,2,5-THIADIAZOLE AND 1,2,5-OXADIAZOLE COMPOUNDS | GREENWOOD BEVERLEY (US) | 1998-04-28 | — | — | US | disclosed |
| US-5658932-A | AZACYCLIC COMPOUNDS; COGNITIVE FUNCTION STIMULANTS; ALZHEIMER'S DISEASE | NOVO NORDISK A/S (DK) | 1997-08-19 | — | — | US | disclosed |
| EP-0788357-A1 | A METHOD OF TREATING URINARY BLADDER DYSFUNCTIONS | NOVO NORDISK A/S (DK) | 1997-08-13 | — | — | EP | disclosed |
| EP-0734259-A1 | ANTIPSYCHOTIC METHOD | NOVO NORDISK A/S (DK) | 1996-10-02 | — | — | EP | disclosed |
| EP-0732925-A1 | A METHOD OF TREATING GASTROINTESTINAL MOTILITY DISORDERS | NOVO NORDISK A/S (DK) | 1996-09-25 | — | — | EP | disclosed |
| US-5559136-A | Treatment of Alzheimer's disease using azacyclic compounds | NOVO NORDISK A/S (DK) | 1996-09-24 | — | — | US | disclosed |
| US-5545638-A | USING A 3-(TETRAHYDROPYRID-3-YL-) SUBSTITUTED (OXA- OR THIA-)DIAZOLE COMPOUND | NOVO NORDISK A/S (DK) | 1996-08-13 | — | — | US | disclosed |
| WO-1996014066-A1 | A METHOD OF TREATING URINARY BLADDER DYSFUNCTIONS | NOVO NORDISK A/S (DK) | 1996-05-17 | — | — | WO | disclosed |
| EP-0687265-A1 | HETEROCYCLIC COMPOUNDS AND THEIR PREPARATION AND USE | NOVO NORDISK A/S (DK) | 1995-12-20 | — | — | EP | disclosed |
| WO-1995017185-A1 | A METHOD OF TREATING GASTROINTESTINAL MOTILITY DISORDERS | NOVO NORDISK A/S (DK) | 1995-06-29 | — | — | WO | disclosed |
| WO-1995005174-A1 | ANTIPSYCHOTIC METHOD | NOVO NORDISK A/S (DK) | 1995-02-23 | — | — | WO | disclosed |
| US-5376668-A | Cholinergic agents as cognition activators in treatment of Alzheimer*s disease | NOVO NORDISK A/S (DK) | 1994-12-27 | — | — | US | disclosed |
| WO-1994020495-A1 | HETEROCYCLIC COMPOUNDS AND THEIR PREPARATION AND USE | NOVO NORDISK A/S (DK) | 1994-09-15 | — | — | WO | disclosed |